B5.jpg b5_ph.jpg
Milestones

2021

  • May.2021
    AffaMed Therapeutics Announces Approval for the Phase IIb Clinical Study of AM006 in China for the Treatment of Parkinson’s Disease
  • May.2021
    AffaMed Therapeutics Announces Appointment of Vijay Karwal as Chief Financial Officer
  • Mar.2021
    AffaMed Therapeutics and SIFI announce Joint Venture to serve Greater China Market
  • Mar.2021
    Affamed Therapeutics announces completion of over US$170 million series B financing and appoints Dr. Ji Li as President and Board Member

2020

  • Oct.2020
    AffaMed Therapeutics and Ocular Therapeutix announce license agreement and collaboration for DEXTENZA® and OTX-TIC in Asia
  • Oct.2020
    AffaMed Therapeutics and EverInsight Therapeutics merged with Dayao Zhao, M.D., Ph.D. appointed as CEO
  • Jun.2020
    EverInsight Therapeutics and VistaGen Therapeutics Enter Strategic Collaboration to Develop and Commercialize PH94B for Anxiety Disorders in Greater China, South Korea and Southeast Asia

2019

  • Aug.2019
    EverInsight Therapeutics established
  • Feb.2019
    AffaMed Therapeutics partners with Samsung Bioepis to develop and commercialize biosimilars in China
  • Feb.2019
    AffaMed Therapeutics established